Skip to main content

Table 2 Literature review – patient characteristics, treatment and outcomes – abbreviations and reference list

From: Primary pancreatic lymphoma – pancreatic tumours that are potentially curable without resection, a retrospective review of four cases

Name (Country) Year n Pathology (number of cases) Successful non-operative biopsy Resection Chemotherapy Radiotherapy Outcome without resection, chemotherapy or RT Outcomes with resection Outcomes with chemotherapy without resection or RT Outcomes with chemotherapy and RT without resection
Hart USA 1987 14 Histiocytcic (9)
Poorly diff lymphocytic (2)
Well diff lymphocytic (1)
T cell (1)
Undifferentiated (1)
0 of 14 1 of 14 CHOP (14) 1 of 14 0 1 NR
(Received CHOP, RT NR)
6 alive at mean 32 months (18–48 months)
2 died within 3 months
5 died at mean 35 months (6–108)
(5 of 13 received RT)
Webb USA 1989 2** DLBCL (6)
Follicular mixed (2)
Small cleaved (1)
  1 of 2 MACOP-B (1) 0 of 2 0 1 alive at 95 months
(Received CAMEL, 0 RT)
1 alive at 21 months 0
Mansour England 1989 12 NR 0 of 12 1 of 12 CHOP (9) 5 of 12 2 died in post-op period after bypass 1 NR
(Received chemo, RT NR)
4 alive at 3,36,48,84 months
5 died at 2–11 months
(5 of 9 received RT)
Tuchek USA 1993 7 NR 0 of 7 0 of 7 CHOP (1)
CVP (1)
CAMEL (1)
0 of 7 4 died – mean survival 5 months 0 3 alive at 60,72,96 months 0
Behrns USA 1994 12 DLBCL (7)
Small cleaved (2)
Mixed (3)
4 of 12 1 of 12 CHOP (4) 4 of 12 2 relapsed or died (NR) 1 NR
(Received chemo, RT NR)
2 died – mean survival 13 months 3 died – mean survival 26 months
(5 died after RT only – mean survival 22 months)
Ezzat Saudi Arabia 1996 5 DLBCL (5) 2 of 5 1 of 5 CHOP (4)
CHOP- Bleo (1)
2 of 5 0 1 alive at 23 months
(Received CHOP, 0 RT)
2 alive at 24,24 months 2 alive at 30,84 months
Bouvet USA 1997 11 DLBCL (10)
Mixed follicular (1)
6 of 11 3 of 11 See legend* 7 of 11 0 3 alive at 11,13,23 months
(All received CHOP, OPEN or CHOP-Bleo, 0 RT)
1 alive at 191 months 4 alive at 44,55,67,159 months
3 died at 12,16,80 months
Koniaris USA 2000 8 DLBCL (7)
Mixed follicular (1)
3 of 8 3 of 8 CHOP (6)
MACOP-B (1)
5 of 8 0 3 alive at 53,62,64 months
(2 received CHOP and RT)
1 alive at 24 months 2 alive at 51,128 months
2 died at 9,37 months
Nishimur a Japan 2001 19 DLBCL (9)
B Immunocytoma (2)
B follicular (2)
T peripheral (3)
T anaplastic large (1)
2 of 19 10 of 19 CHOP (5)
Mitomycin (1)
Tegafur (1)
Unspecified chemo (1)
0 of 19 7 died at 1,2,2,3,8,60,72 months 4 died at 9,10,11,27 months
4 alive at 3,4,12,19 months
2 ND
(6 received chemo, 4 no chemo, 0 RT)
2 died at 2,8 months 0
Nayer USA 2004 8 DLBCL (4)
High grade B cell (1)
Low grade B (2)
Suspicious (1)
8 of 8 0 of 8 Chemo (4)
Chemo and auto SCT (2)
NR (2)
3 of 8
(2 NR)
0 0 3 alive at 5,6,76 months 3 alive at 2,7,72 months
Arcari Italy 2005 5 DLBCL (3)
Lymphoplasmacytic (2)
3 of 5 2 of 5 CVP/CHO
P (3)
CHOP (1)
CVP (1)
2 of 5 0 1 alive at 160 months
1 died at 8 months
(Received CHOP or CVP, 0 RT)
1 alive at 60 months
2 died at 67, 88 months
(2 of 3 received RT)
Grimison Australia [current series] 2005 4 DLBCL (3)
Follicular (1)
1 of 4 0 of 4 CHOP (2)
Rituximab- CHOP (1)
CVP (1)
4 of 4 0 0 0 1 died 32 months
3 alive 15,25,64 months
Overall   107 cases inc. current series   Excluding 2 NR:
29 of 105
23 of 107 80 of 107 Excluding 2 NR:
33 of 105
Excluding 2 NR:
0% (0 of 15) NED
Mean 13 months
2YS 13% (2 of 15)
Excluding 5 NR:
72% (13 of 18) NED
Mean 34 months
2YS 33% (6 of 18)
57% (36 of 63) NED
Mean 38 months
2YS of 62% (28 of 45) – excludes 18 NR
 
  1. *CHOP (1), CHOP-Bleomycin (2), CHOP-OPEN (2), CHOP-Bleomycin, CMED, ESHAP (1), CHOP-Bleomycin, OPEN (1), CHOP, OAP-Bleomycin, MIME (1), CHOP-Bleomycin, MINE, ESHAP, Autologous SCT (1), IM-Etop, HOP (1), ESHAP, BACOS, MIME (1)
  2. **excludes 7 patients with stage III/IV NHL
  3. BACOS – bleomycin, doxorubicin, cyclophosphamide, vincristine, methylprednisolone
  4. CAMEL – cyclophophamide, adriamycin, vincristine, prednisone Chemo – chemotherapy
  5. CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone
  6. CMED – cyclophosphamide, methotrexate, etoposide, dexamethasone
  7. CVP – cyclophosphamide, vincristine, prednisone
  8. DLBCL – diffuse large Bcell lymphoma
  9. ESHAP – etoposide, methyprednisolone, high-dose cytarabine, cisplatin
  10. HOP – doxorubicin, vincristine, prednisone
  11. IM-etop – ifosfamide, methotrexate, etoposide
  12. MACOP-B
  13. MIME – MESNA, ifosfamide, methotrexate, etoposide
  14. MINE – MESNA, ifosfamide, mitoxantrone, etoposide
  15. NED – no evidence of disease
  16. NR – not reported
  17. OAP-Bleomycin – vincristine, cytarabine, prednisone, bleomycin
  18. OPEN – vincristine, prednisone, etoposide, mitoxantrone
  19. RT – radiotherapy
  20. SCT – stem cell transplantation
  21. References for table 2 – Hart[12], Webb[22], Mansour.[45], Tuchek[47], Behrns.[2], Ezzat[48], Bouvet.[21], Koniaris[23], Nishimura[49], Nayer.[3], Arcari[20]